mitoxantrone liposome + polatuzumab vedotin

**Mitoxantrone liposome + polatuzumab vedotin** is an investigational combination regimen consisting of liposomal mitoxantrone hydrochloride, a formulation of the anthracycline **mitoxantrone** that intercalates DNA and inhibits topoisomerase II to induce cancer cell death with reduced cardiotoxicity compared to conventional anthracyclines, and **polatuzumab vedotin**, a CD79b-targeted antibody-drug conjugate (ADC) that delivers the microtubule disruptor monomethyl auristatin E (MMAE) payload to B-cells via internalization and lysosomal cleavage. Primarily explored in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), particularly as bridging therapy to CAR-T or in elderly/frail patients intolerant to standard regimens like R-CHOP; retrospective studies report high efficacy with complete metabolic responses and tolerable safety, including manageable myelosuppression.[5][16][18]

Other names

mitoxantrone hydrochloride liposome + polatuzumab vedotinLipo-MIT + polatuzumab vedotin